Loading clinical trials...

Topical Tacrolimus 0.1% Ointment For Treatment Of Cutaneous Crohn's Disease | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Topical Tacrolimus 0.1% Ointment For Treatment Of Cutaneous Crohn's Disease

Topical Tacrolimus 0.1% Ointment for Treatment of Cutaneous Crohn's Disease

NCT01233570•University of Aberdeen

View on ClinicalTrials.gov

Summary

An assessment of the efficacy of topical tacrolimus in the treatment of cutaneous crohns disease

Eligibility

Age

12 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•willingness and capability to follow the study procedure
•confirmed diagnosis of Crohn's Disease of at least 3 months duration confirmed by radiography, endoscopy or pathological examination
•required to have a skin manifestation of Crohn's disease
•required to give written informed consent
•both male and female subjects with reproductive potential required to be on an acceptable form of birth control for the duration of the study
•long-standing, concomitant immunosuppressive therapy was allowed if the dose was stable and not controlling the skin problem

Exclusion Criteria

•known sensitivity to tacrolimus
•change in aminosalicylate dosage in the four weeks prior to screening
•on oral steroids at over 40mg per day
•been commenced on methotrexate, azathoprine or ciclosporin within the last two months
•commenced on a a TNF-alpha monoclonal antibody within the three months prior to screening
•patients having had a stoma fashioned less than three months before enrolment
•patients with an immunocompromising disease
•patients with a diagnosis of malignancy within the last five years
•patients with any other condition, past or present treatment thought by the investigator to render the subject ineligible for the study

Locations (1)

University of Aberdeen, Aberdeen Royal Infirmary

Aberdeen, Grampian, United Kingdom

Key Dates

Last Updated

November 3, 2010

Enrollment

ACTUAL participants

Conditions

Crohn Disease

Interventions

Tacrolimus

DRUG

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

NCT07245394

Inflammatory Bowel Disease (IBD)Crohn Disease (CD)+2 more

View study

RECRUITING

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

NCT07089420

IBD (Inflammatory Bowel Disease)IBS - Irritable Bowel Syndrome+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 3, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Topical Tacrolimus 0.1% Ointment For Treatment Of Cutaneous Crohn's Disease

Inclusion Criteria

Exclusion Criteria

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

Immunological Characteristics of Preclinical IBD

Impact of Exclusion Diet in Addition to Anti-TNF Therapy in Crohn's Disease and Ulcerative Colitis: a Prospective, Randomized, Double-arm, Open-label Study

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

Robotic Inflammatory Bowel Disease Development, Learning and Efficacy Study